Please activate JavaScript!
Please install Adobe Flash Player, click here for download
ePaper created 2017-12-06, 11:14:19 | version 1.38.0
news Straumann and Rapid Shape to Drive 3-D printing technology In June, Straumann and Rapid Shape announced that they have expanded their partnership with the goal of accelerating the uptake of 3-D print- ing technology in dentistry. Straumann has pur- chased a 35 per cent non-controlling stake in the Germany-based company for an undisclosed sum, enabling Rapid Shape to invest further in development and production, as well as increas- ing its service footprint. The acquisition follows a non-exclusive distribution agreement signed in March, allowing Straumann to supply Rapid Shape 3-D printers worldwide. Rapid Shape, however, will maintain its open business model of non-exclusive distri- bution partnerships. © doomu/Shutterstock.com Rapid Shape’s 3-D printers are designed to en- able dental laboratories to produce temporary prosthetic restorations, models and drill tem- plates for guided surgery with certifi ed precision very effi ciently. An open-system approach allows customers to choose from a wide variety of certifi ed materials from multiple suppliers. Straumann will sell the printers under its own brand, offering seamless connectivity with its validated digital workfl ow for tooth replacement. According to industry intelligence, the installed base and output of dental 3-D printers are expected to triple over the next fi ve years, Straumann announced. 56 implants 3 2017 Alpha-Bio Tec launches its Scientifi c Research Collaboration Programme At this year’s EAO congress in Madrid, Spain, Alpha-Bio Tec will be launching its Scientifi c Research Collaboration Programme for the spon- sorship of clinical and preclinical studies in dental implantology, tissue regeneration and dental pros- thetics. Additionally, participants will be able to ex- perience live Alpha-Bio Tec’s new NeO implant and CAD/CAM guided surgery tool kit. Alpha-Bio Tec will also take part in the EAO research poster ex- hibition, offering a unique opportunity to meet Prof. Ofer Moses and Dr Zoabi Hasan, who will be pre- senting two studies selected by the EAO, which are an in vitro comparative study of bacterial growth on grooved and non-grooved healing abutments and the effect of coronal implant design and drilling pro- tocol on bone-to-implant contact. At the lunch symposium, Alpha-Bio Tec will be hosting Prof. Ofer Moses and Prof. Dieter Boss- hardt with their lecture “The way to Ithaka: From vision to clinical implication”. The lecture will discuss the combination of vision, open minds, animal models and surgical skills in revolution- ary surgical solutions exploring implant housing biology, and collaboration with histology experts to obtain high-quality results and the implications for academic and clinical use. Source: Alpha-Bio Tec Dr Karsten Wagner is now responsible for The global development of Ankylos and Xive Dr Karsten Wagner is taking over the position of Global Director Platform Implant Systems Ankylos/ X ive at Dentsply Sirona Implants. This means that he will be responsible for product innovation and brand strategy for the Ankylos and Xive implant systems worldwide. Dr Wagner, CEO of Dentsply Sirona Implants Germany, has initiated successful events for both implant systems with the Xive Roadshow and the Ankylos Congress in Germany, which also attracted a great deal of interest internationally. Now he can bring his strategies to the global pro- motion of the premium dental implant brands. His excellent customer contacts and many years of experience in the dental market will be of great benefi t in this role. Dr Karsten Wagner is solidly anchored in medical technology. After working at Abbott, where he gained experience in sales, product management and later as Head of Key Account Management, he then switched to National Sales Manager of the former Astra Tech GmbH in 2004, and became Business Unit Director in 2008. With the merger of Astra Tech Dental and DENTSPLY Friadent into DENTSPLY Implants in 2013, Dr Wagner was fi rst responsible for sales, then became CEO in Ger- many and took over the overall management of sales for the D-A-CH region (Germany, Austria, Switzerland). He is also retaining the function of CEO of Implants in Germany in order to oversee the planned restructuring measures in Germany.